Grifols Achieves Positive Topline Results From Phase 4
Clinical trial met primary endpoint demonstrating comparable total immunoglobulin (Ig) levels when administering XEMBIFY® (Grifols’ subcutaneous Ig) every...
Source: globenewswire.com
Global Usage News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Global Usage. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Global Usage Today - Breaking & Trending Today
People are already bored of Meta's Twitter rival Threads as daily usage drops by 50 per cent in just 10 days
Threads, the fast-growing app that gained over 150 million downloads in just 10 days, is facing a drop in daily usage by almost 50 percent, with users now spending only 10 minutes per day on the platform. Despite this setback, Meta plans to introduce more features similar to Twitter in hopes of increasing usage and improving the user experience, while India leads in app downloads followed by Brazil and the United States.
Source: indiatoday.in
Grifols begins European launch of XEMBIFY in Spain to treat immunodeficiencies
Barcelona, Spain - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global leader in plasma medicines, has started marketing XEMBIFY®, its 20% subcutaneous immunoglobulin, in Spain. This plasma medicine is indicated for treating primary immunodeficiencie...
Source: marketscreener.com
Grifols S A : begins European launch of XEMBIFY® in Spain to treat immunodeficiencies
June 26, 2023 Grifols begins European launch of XEMBIFY® in Spain to treat immunodeficiencies Print this news Download the press release Primary immunodeficiencies (PID) affect...
Source: marketscreener.com
Usage based Insurance For Automotive Market May Set Massive Growth by 2026 | Progressive, Allstate, Liberty Mutual
Usage based Insurance For Automotive Market May Set Massive Growth by 2026 | Progressive, Allstate, Liberty Mutual
Source: sandiegosun.com